AZN vs LGVN · P/E 28, $288.38B cap vs rev $2.4M
AstraZeneca PLC (AZN) versus Longeveron LLC (LGVN) — a side-by-side from cached financials, not a winner call.
AstraZeneca PLC (AZN) is a drug manufacturers - general company listed on US.
Longeveron LLC (LGVN) is a biotechnology company listed on NASDAQ.
AZN does not have a complete income-statement cache yet.
Latest reported LGVN revenue for 2024-12-31 was $2.4M. Net income was -$16.0M. Revenue was up 237.4% from 2023-12-31 to 2024-12-31. LGVN currently screens at market cap $26.5M.
AZN currently screens at market cap $288.38B and trailing P/E 28.0. LGVN currently screens at market cap $26.5M.
Not investment advice. Open the AZN and LGVN stock pages for the full models.
Not investment advice.